Kymera Therapeutics (NASDAQ:KYMR) Director Sells $13,540,707.20 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 134,720 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $100.51, for a total transaction of $13,540,707.20. Following the completion of the transaction, the director owned 597,047 shares in the company, valued at $60,009,193.97. This represents a 18.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The stock was sold at an average price of $121.86, for a total value of $34,813,452.24.
• On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The stock was sold at an average price of $115.39, for a total value of $30,305,683.43.
• On Tuesday, June 23rd, Bruce Booth sold 1,408 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.98, for a total transaction of $140,771.84.
• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The shares were sold at an average price of $98.52, for a total transaction of $24,268,431.60.
• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.01, for a total transaction of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.38, for a total value of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total value of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The stock was sold at an average price of $103.75, for a total transaction of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.08, for a total transaction of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.96, for a total value of $530,764.00.

Kymera Therapeutics Price Performance

NASDAQ:KYMR traded up $16.59 during trading hours on Thursday, reaching $116.46. 3,915,007 shares of the stock were exchanged, compared to its average volume of 826,395. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $130.05. The firm has a 50 day moving average of $84.43 and a 200 day moving average of $82.12. The stock has a market cap of $9.58 billion, a PE ratio of -32.62 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. During the same period in the previous year, the business earned ($0.82) EPS. The company’s revenue was up 55.5% compared to the same quarter last year. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera announced that enrollment in its Phase 2b BROADEN2 trial of KT-621 for moderate to severe atopic dermatitis was completed nearly six months ahead of schedule, with topline data expected by year-end 2026. The accelerated timeline also supports the company’s broader development plans for KT-621, including a planned Phase 3 start by mid-2027. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG Research reaffirmed its buy rating and set a $134 price target, implying additional upside if the clinical program continues to progress. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: The company also announced Felix J. Baker, Ph.D. as chairman of the board, a leadership change that may help support oversight but is less likely to move the stock on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
• Negative Sentiment: Insider Noah Goodman sold 5,000 shares at $114 each, which can sometimes be viewed as a cautious signal, though the sale was relatively small versus his remaining holdings. Article: Insider transaction filing

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its stake in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Kymera Therapeutics in the 4th quarter valued at $63,000. Osaic Holdings Inc. increased its stake in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Kymera Therapeutics by 56.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock worth $107,000 after buying an additional 463 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have commented on KYMR shares. BTIG Research reiterated a “buy” rating and issued a $134.00 price target on shares of Kymera Therapeutics in a research note on Thursday. Jefferies Financial Group began coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 target price on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $119.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Citigroup boosted their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $117.14.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.